



EP00/1443

The
Patent
Office

REC'D 30 MAR 2000

WIPO

PCT

PCT/EP00/0144



INVESTOR IN PEOPLE

EPO - DG 1

23. 02. 2000

(86)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

4

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Signed *Andrew Gersey*
Dated 19 January 2000



THIS PAGE BLANK (USPTO)



08MAR99 E430580-1 D10009
P01/7700 0.00 - 9905134.4

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference

CGP / PG3605

2. Patent application number

(The Patent Office will fill in this part)

9905134.4

3. Full name, address and postcode of the or of each applicant (underline all surnames)

GLAXO GROUP LTD
GLAXO WELLCOME HOUSE
BERKELEY AVENUE

Patents ADP number (if you know it)

GREENFORD

If the applicant is a corporate body, give the country/state of its incorporation

MIDDLESEX UB6 0NN
UNITED KINGDOM

473587003

4. Title of the invention

MEDICAMENT DELIVERY SYSTEM

5. Name of your agent (if you have one)

DR CHRISTOPHER F PIKE

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

PIKE & CO.
3 KLONDYKE
MARLOW
BUCKS
SL7 2QQ

Patents ADP number (if you know it)

7497928001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

YES

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0

Description 10

Claim(s) 5

Abstract 1

Drawing(s) 5+5

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

DR CG PIKE

Date 5 MARCH 1979

DR CG PIKE - AGENT FOR THE APPLICANT

12. Name and daytime telephone number of person to contact in the United Kingdom

DR C G PIKE 01628 471869

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Medicament delivery system

5 The present invention relates to a system for the delivery of inhalable medicament to a patient at a preset point in the breathing pattern of the patient. In particular, the invention relates to metered dose inhalers by means of which medicament may be delivered in metered doses.

10 It is well known to treat patients with medicaments contained in an aerosol, for example, in bronchodilator therapy. It is also known to use for such therapy, medicaments which are contained in an aerosol and are administered to a patient by means of an inhalation device comprising a tubular housing or sleeve in which the aerosol container is located and an outlet tube leading out of the tubular housing. The aerosol containers used in such inhalation devices are
15 designed to deliver a predetermined dose of medicament upon each actuation by means of an outlet valve member at one end which can be opened either by depressing the valve member while the container is held stationary or by depressing the container while the valve member is held stationary. In the use of such devices, the aerosol container is placed in the tubular housing with the
20 outlet valve member of the container communicating via a support with the outlet tube, for example a nozzle or mouthpiece. When used for dispensing medicaments, for example in bronchodilation therapy, the patient then holds the housing in a more or less upright condition and the mouthpiece or nozzle of the inhalation device is placed in the mouth or nose of the patient. The aerosol
25 container is pressed towards the support to dispense a dose of medicament from the container which is then inhaled by the patient.

It may be understood that effective delivery of medicament to the patient using an inhalation device as described above is to an extent dependent on the
30 patient's ability to co-ordinate the actuation of the device (e.g. firing of the aerosol) with the taking of a sufficiently strong inward breath. For some patients the required co-ordination can present difficulties. Other patients, particularly those having severe respiratory problems, find it difficult to produce a reliable inward breath. Both of these sets of patients run the risk that they do not receive
35 the appropriate dose of medicament.

Breath-actuable or breath-assisted inhalation devices have been developed to address the needs of patients having poor co-ordination skills and/or unreliable breath capability. Such devices typically have a breath trigger mechanism which triggers release of medicament in response to the inward breath of a patient.

One problem inherent with such breath-triggered devices is that a certain amount of the inward breath is used up before the trigger is activated. The full inward breath is thus, not available for inhalation of medicament. Further, that initial part of the inward breath which is 'lost' prior to release of the medicament is a relatively strong and inhalation-effective portion of the full inward breath. Where the patient has poor breath capacity the loss of this portion of the inward breath may significantly compromise the amount of medicament which is deliverable by the device to the lungs.

Another problem with such breath-triggered devices is that the medicament may not be released at the optimum point in the breath cycle.

The Applicants have now found that enhanced delivery of medicament is achievable by use of a system in which the breathing pattern of a patient is monitored and drug release is co-ordinated with a preset point in the breathing pattern. This preset point is selected to optimise the delivery of drug to the lung. It has been found to be particularly advantageous if the preset point is defined relative to, or indeed to coincide with, the end of the exhalation part of the breath cycle.

The Applicants have also now appreciated that at the end of the exhalation part of the breath cycle, the patient's mouth cavity is typically at rest which allows it to act as a natural 'spacer' element, thereby assisting with dispersal of the delivered medicament. There is thus, potentially less need for the use of a separate mechanical spacer element as is commonly used in conjunction with the mouthpiece of conventional inhalation devices.

According to one aspect of the present invention there is provided a system for the delivery of inhalable medicament comprising a monitor for monitoring the

breath cycle of a patient; a medicament container having a release mechanism for releasing inhalable medicament therefrom; and an actuator for actuating said release mechanism, said actuator being actuatable in response to a signal from said monitor. The monitor provides said signal at a trigger point which is coupled to the end of the exhalation part of the breath cycle.

Preferably, the monitor comprises one or more sensors for sensing the pressure profile associated with the breath cycle of the patient.

Preferably, the monitor comprises one or more sensors for sensing the airflow profile associated with the breath cycle of the patient.

Preferably, the monitor comprises one or more sensors for sensing the temperature profile associated with the breath cycle of the patient. The temperature of the inhaled and exhaled part of the breath cycle varies and may, thus, be used as a measurement tool.

Preferably, the monitor comprises one or more sensors for sensing the moisture profile associated with the breath cycle of the patient. The moisture content of the inhaled and exhaled part of the breath cycle varies and this also may be used as a measurement tool.

Preferably, the monitor comprises one or more sensors for sensing the chemical profile, particularly the oxygen or carbon dioxide profile, associated with the breath cycle of the patient. The chemical profile of the inhaled and exhaled part of the breath cycle varies and this further may be used as a measurement tool.

Preferably, the monitor is connectable to an electronic information processor.

Preferably, the electronic information processor includes an active memory for storing information about successive breath cycles and a predictive algorithm for predicting the optimum trigger point. Alternatively, reference may be made to a look-up table for predicting the optimum trigger point. More preferably, the optimum trigger point corresponds to the point at which the lungs of the patient are empty.

Preferably, the electronic information processor includes a second predictive algorithm or look-up table for predicting the optimum amount of medicament to release. In general, a real-time analysis of the patient waveform is made and the prediction is made by reference to that analysed waveform. More preferably, the electronic information processor includes a dose memory for storing information about earlier delivered doses and reference is made to the dose memory in predicting the optimum amount of medicament to release.

In one preferred aspect, the medicament container is an aerosol container and said release mechanism is an aerosol valve. More preferably, the aerosol valve includes a metering chamber for metering the release of medicament.

In another preferred aspect, the medicament container is a dry-powder container, that is to say a container suitable for containing medicament in dry-powder form.

Preferably, the actuator comprises an energy store for storing energy which energy is releasable to activate the release mechanism of the medicament container. The energy store comprises in preferred aspects, a biasable resilient member such as a spring, a source of compressed fluid such as a canister of compressed gas, or a battery. Chemical energy sources are also suitable and might include chemical propellant or ignition mixtures. Other sources might include physical explosives such as liquefied or solidified gas in a canister which burst when heated or exposed to the atmosphere.

Preferably, the system additionally comprises a safety mechanism to prevent rapid multiple actuations of the actuator. The patient is thereby protected from inadvertently receiving multiple doses of medicament in a situation where they take a number of short rapid breaths. More preferably, the safety mechanism imposes a time delay between successive actuations of the actuator. The time delay is typically of the order of from three to thirty seconds.

An actuation counter which can be mechanical or electronic may be provided to the system.

5 A drug release counter, such as a dose counter, may be provided to the system. This may be mechanical or electronic. The counter may be coupled to a visual display to provide feedback to the patient as to amount of drug released or remaining in the container.

A manual override can be provided to the system for use in the event of emergency or system failure.

10 According to another aspect of the present invention there is provided an inhalation device for the delivery of inhalable medicament comprising a housing and a system as described above.

15 According to a further aspect of the present invention there is provided a method for the delivery of inhalable medicament to a patient comprising

(i) monitoring the breath cycle of a patient by use of a monitor;

20 (ii) at a trigger point, sending an actuation signal from said monitor to an actuator;

(iii) on receipt of said actuation signal by said actuator, actuating the release of inhalable medicament to the patient,

25 The trigger point is coupled to the end of the exhalation part of the breath cycle.

30 In step (i) a real-time analysis of the patient waveform may be made and comparison made with a medically acceptable waveform. Steps (i) to (iii) can then repeated until the patient waveform sufficiently matches the medically acceptable waveform.

Preferably, the method comprises

35 (i) monitoring a plurality of breath cycles of a patient by use of a monitor;

(ii) analysing said plurality of breath cycles to define an averaged breath cycle for the patient;

5 (iii) predicting a predicted trigger point from said averaged breath cycle, the predicted trigger point being coupled to the end of the exhalation part of the averaged breath cycle;

10 (iv) monitoring a further breath cycle and at said predicted trigger point sending an actuation signal from said monitor to an actuator;

(v) on receipt of said actuation signal by said actuator, actuating the release of inhalable medicament to the patient.

15 A system according to the invention will now be described with reference to the accompanying drawings in which:

Figure 1. is a sectional view of a standard metered dose inhaler;

20 Figure 2. is a perspective view of an inhalation device in accord with the present invention;

Figure 3. is a graphical representation of a patient breathing pattern;

25 Figure 4. is a schematic representation of a system in accord with the present invention; and

Figure 5. is a flow-chart indicating the operation of a system in accord with the present invention.

30 The standard metered dose inhaler shown in Fig 1 comprises a tubular housing 1 in which an aerosol container 2 can be located. The housing is open at one end (which will hereinafter be considered to be the top of the device for convenience of description) and is closed at the other. An outlet 3 leads laterally from the closed end of the housing 1. In the embodiment illustrated, the
35 outlet 3 is in the form of a mouthpiece intended for insertion into the mouth of

the patient but it may, if desired, be designed as a nozzle for insertion into the patient's nostril.

5 The aerosol container 2 has an outlet valve stem 4 at one end. This valve member can be depressed to release a measured dose from the aerosol container or, alternatively, the valve stem 4 can be fixed and the main body of the container can be moved relative to the valve member to release the dose.

10 As shown clearly in Fig 1, the aerosol container 2 is located in the housing 1 so that one end protrudes from its open top. Spacer ribs (not shown) may be provided inside the housing to hold the external surface of the container 2 spaced from the internal surface of the housing 1. A support 5 is provided at the lower end of the housing 1 and has a passage 6 in which the valve stem 4 of the aerosol container 2 can be located and supported. A second passage 7 is
15 provided in the support 5 and is directed towards the interior of the outlet 3.

20 Thus, when the parts are in the positions shown in Fig 1, the protruding portion of the aerosol container 2 can be depressed to move the container relative to the valve stem 4 to open the valve and a dose of medicament contained in the aerosol will be discharged through the passage 7 and into the outlet 3 from which it can be inhaled by a patient. One dose will be released from the aerosol container each time it is fully depressed.

25 Figure 2. shows a metered dose inhaler of the general type illustrated in Figure 1. which includes an electronic device for monitoring the breath cycle of a patient. The device comprises housing 20 within which an electronic information processor is housed. The electronic information processor is connected to a sensor (not visible) for sensing the breathing pattern of the patient and an actuator (not visible) for actuating the release of aerosol from the container 2.
30 Visual display monitor 30 allows for display of information relating to doses dispensed from the container 2.

35 Figure 3. depicts the breathing pattern of a patient in simplified graphical form wherein the vertical axis represents the volume of air in the lungs and the horizontal axis represents time. A trigger zone 40 is indicated which

corresponds to the portion in the breath cycle at which the lungs are at their most empty.

Figure 4. is a block diagram illustrating a system herein. Inhaler 10 includes pressure or flow transducers 40 for the sensing of pressure or flow profile through the device, thereby enabling the breathing pattern of a patient to be monitored. The pressure or flow transducers 40 connect via amplifier 42 and analogue to digital converter 44 to micro-controller 50. The micro-controller 50 is for example, contained within a device attached to the inhaler 10 (as in Figure 2.). The micro-controller 50 is in communication with a user display 30 for the visual display of information e.g. relating to number of doses dispensed. The micro-controller 50 is also in communication with a memory 60 for storage of information relating to the breathing pattern of the patient. The micro-controller 50 further communicates with an interface 70 to an external computer system 72. The external computer system 72 allows for the use of customised software such as that enabling visual display of the breathing pattern of the patient. Importantly, the micro-controller 50 also communicates with an actuator on the inhaler 10, thereby enabling an actuation signal to be sent at the appropriate trigger point.

Figure 5. is a flow diagram illustrating a method of use of a system in accord with the invention. At point 80 the equipment is powered up, typically from a low energy 'sleep' mode. Pressure or flow readings are then taken at point 82. These readings are analysed at point 83 and corrections made for any artefacts such as if the patient coughs or takes short, sudden breaths. A picture of the patient's breathing pattern is, thus, assembled. At point 84 an assessment is made as to whether the patient is at the end of the exhalation part of the breath cycle. The trigger point is at the end of breath point, or at a point coupled thereto. At point 85 a calculation is made of the dose required. The calculation is based on trend data and on the current breathing pattern. At point 86 the dose is fired. A loop involving an optional programmable delay 87 may be included to allow for the delivery of dose by multiple, rapid firing of partial doses. At point 88 a check is made if the patient requires further doses. If further doses are required, there is a loop back to point 82.

If no further doses are required, point 90 is reached at which a calculation is made of the total dose delivered in the most recent firing pattern and the dose display is updated. Data relating to the most recent dose delivery event is logged into a memory at point 92. A delay is triggered at point 94 to prevent reuse of the system within a set time period. This delay acts as a safety mechanism. At point 96, the system is reset to the powered down 'sleep' mode.

The system of the invention is suitable for dispensing medicament, particularly for the treatment of respiratory disorders. Appropriate medicaments may thus be selected from, for example, analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate, ketotifen or nedocromil; anti-infectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g., methapyrilene; anti-inflammatories, e.g., beclomethasone dipropionate, fluticasone propionate, flunisolide, budesonide, rofleponide, mometasone furoate or triamcinolone acetonide; antitussives, e.g., noscapine; bronchodilators, e.g., albuterol, salmeterol, ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, tulobuterol, or (-)-4-amino-3,5-dichloro- α -[[[6-[2-(2-pyridinyl)ethoxy]hexyl]methyl] benzenemethanol; diuretics, e.g., amiloride; anticholinergics, e.g., ipratropium, tiotropium, atropine or oxitropium; hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines, e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; therapeutic proteins and peptides, e.g., insulin or glucagon. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts, (e.g., as alkali metal or amine salts or as acid addition salts) or as esters (e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimise the activity and/or stability of the medicament.

Preferred medicaments are selected from albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof, e.g., the sulphate of albuterol and the xinafoate of salmeterol.

5 Medicaments can also be delivered in combinations. Preferred formulations containing combinations of active ingredients contain salbutamol (e.g., as the free base or the sulphate salt) or salmeterol (e.g., as the xinafoate salt) in combination with an antiinflammatory steroid such as a beclomethasone ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate).

10 It will be understood that the present disclosure is for the purpose of illustration only and the invention extends to modifications, variations and improvements thereto.

15 The application of which this description and claims form part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described therein. They may take the form of product, method or use claims and may include, by way of example and without limitation, one or more of the following claims:

CLAIMS:

1. A system for the delivery of inhalable medicament comprising

5 a monitor for monitoring the breath cycle of a patient;

a medicament container having a release mechanism for releasing inhalable medicament therefrom; and

10 an actuator for actuating said release mechanism, said actuator being actuable in response to a signal from said monitor,

characterized in that the monitor provides said signal at a trigger point which is coupled to the end of the exhalation part of the breath cycle.

15

2. A system according to claim 1, wherein said monitor comprises one or more sensors for sensing the pressure profile associated with the breath cycle of the patient.

20

3. A system according to either of claims 1 or 2, wherein said monitor comprises one or more sensors for sensing the airflow profile associated with the breath cycle of the patient.

25

4. A system according to any of claims 1 to 3, wherein said monitor comprises one or more sensors for sensing the temperature profile associated with the breath cycle of the patient.

30

5. A system according to any of claims 1 to 4, wherein said monitor comprises one or more sensors for sensing the moisture profile associated with the breath cycle of the patient.

35

6. A system according to any of claims 1 to 5, wherein said monitor comprises one or more sensors for sensing the oxygen or carbon dioxide profile associated with the breath cycle of the patient.

7. A system according to any of claims 1 to 6, wherein said monitor is connectable to an electronic information processor.

8. A system according to claim 7, wherein said electronic information processor includes an active memory for storing information about successive breath cycles and a predictive algorithm for predicting the optimum trigger point.

9. A system according to claim 7, wherein said electronic information processor includes an active memory for storing information about successive breath cycles and a look-up table for predicting the optimum trigger point.

10. A system according to either of claims 8 or 9, wherein said optimum trigger point corresponds to the point at which the lungs of the patient are empty.

11. A system according to any of claims 8 to 10, wherein said electronic information processor includes a second predictive algorithm or look-up table for predicting the optimum amount of medicament to release.

12. A system according to claim 11, wherein said electronic information processor includes a dose memory for storing information about earlier delivered doses and reference is made to the dose memory in predicting the optimum amount of medicament to release.

13. A system according to any of claims 1 to 12, wherein said medicament container is an aerosol container and said release mechanism is an aerosol valve.

14. A system according to claim 13, wherein said aerosol valve includes a metering chamber for metering the release of medicament.

15. A system according to any of claims 1 to 14, wherein said medicament container is a dry-powder container.

16. A system according to any of claims 1 to 15, wherein said actuator comprises an energy store for storing energy which energy is releasable to activate the release mechanism of the medicament container.

5 17. A system according to claim 16, wherein said energy store comprises a biasable resilient member.

18. A system according to claim 17, wherein said biasable resilient member is a spring.

10

19. A system according to claim 16, wherein said energy store comprises a source of compressed fluid, preferably compressed gas.

15

20. A system according to claim 16, wherein said energy store comprises a battery.

21. A system according to claim 16, wherein said energy store comprises a chemical energy source, preferably a chemical propellant or ignition mixture.

20

22. A system according to claim 16, wherein said energy store comprises a physically explosive energy source.

23. A system according to any of claims 1 to 22, additionally comprising a safety mechanism to prevent rapid multiple actuations of the actuator.

25

24. A system according to claim 23, wherein said safety mechanism imposes a time delay between successive actuations of the actuator.

30

25. A system according to any of claims 1 to 24, additionally comprising an actuation counter.

26. A system according to any of claims 1 to 25, additionally comprising a drug release counter, preferably a dose counter.

27. A system according to any of claims 1 to 26, additionally comprising a manual override.

28. An inhalation device for the delivery of inhalable medicament comprising a housing and a system according to any of claims 1 to 27.

29. A method for the delivery of inhalable medicament to a patient comprising

(i) monitoring the breath cycle of a patient by use of a monitor;

(ii) at a trigger point, sending an actuation signal from said monitor to an actuator;

(iii) on receipt of said actuation signal by said actuator, actuating the release of inhalable medicament to the patient,

characterized in that said trigger point is coupled to the end of the exhalation part of the breath cycle.

30. Method according to claim 29, wherein steps (i) to (iii) are repeated until the breath cycle corresponds to a medically acceptable form.

31. Method according to claim 29, comprising

(i) monitoring a plurality of breath cycles of a patient by use of a monitor;

(ii) analysing said plurality of breath cycles to define an averaged breath cycle for the patient;

(iii) predicting a predicted trigger point from said averaged breath cycle, the predicted trigger point being coupled to the end of the exhalation part of the averaged breath cycle;


(iv) monitoring a further breath cycle and at said predicted trigger point sending an actuation signal from said monitor to an actuator;

5 (v) on receipt of said actuation signal by said actuator, actuating the release of inhalable medicament to the patient.

ABSTRACT

5 There is provided a system for the delivery of inhalable medicament comprising a monitor for monitoring the breath cycle of a patient, a medicament container having a release mechanism for releasing inhalable medicament therefrom, and an actuator for actuating said release mechanism, the actuator being actuable in response to a signal from the monitor. The monitor provides the signal at a trigger point which is coupled to the end of the exhalation part of the breath cycle.

1/5



This page Blank (uspio)

2/5




Fig. 2

This Page Blank (uspto)

INHALE

EXHALE

INHALE

EXHALE

INHALE




Fig. 3

This Page Blank (uspto)

4/5




Fig. 4

This Page Blank (uspto)




Fig. 5

This Page Blank (uspto)

BEST AVAILABLE COPY